Olaparib Under Review by EMA for BRCA-mutated, HER2-negative Breast Cancer

A marketing authorization application for olaparib (Lynparza) for the treatment of women with BRCA-mutated, HER2-negative metastatic breast cancer who previously received chemotherapy in the neoadjuvant, adjuvant, or metastatic setting has been accepted by the European Medicines Agency.

Read full article (External website)

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply